RxDoctor Payments Data

Duane Sossong, DO

Internal Medicine · Randolph, NJNPI 1720021488

Payments from drug & device makers

$584in general payments, 2019–2025

Across 47 payments — averaging $12.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$322
  • AstraZeneca$98
  • Pfizer$30
  • Lilly USA, LLC$29
  • GSK$27
  • Johnson & Johnson$26
  • plus $52 from 3 others

What the payments were for

  • Food & beverage$56797%
  • Education$163%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$584 in reported general payments places this provider in the 55th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$264,122
Medicare patients
326
Services billed
4,203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide95$134,015
EliquisApixaban56$42,838
JanuviaSitagliptin Phosphate29$41,130
TrulicityDulaglutide19$36,110
FarxigaDapagliflozin Propanediol27$32,311
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$26,907
Breo ElliptaFluticasone/Vilanterol32$19,359
MounjaroTirzepatide16$17,933
Tresiba Flextouch U-200Insulin Degludec19$11,248
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$10,108
Dexlansoprazole DrDexlansoprazole21$9,250
Verapamil Er PmVerapamil Hcl12$7,062
SynthroidLevothyroxine Sodium74$5,956
Atorvastatin Calcium315$3,255
Rosuvastatin Calcium261$3,230

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$322$134,01595 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$27$56,37474 claims
Lilly USA, LLCTrulicity, Mounjaro$29$54,04435 claims
PfizerEliquis$30$42,83856 claims
MerckJanuvia$12$41,13029 claims
AstraZenecaFarxiga$98$32,31127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Randolph

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →